齐拉西酮和阿立哌唑治疗精神分裂症的临床对照研究

目的：比较齐拉西酮胶囊和阿立哌唑治疗精神分裂症的疗效和安全性。方法：将80例符合ICD-10的精神分裂症患者随机分为两组,分别给予齐拉西酮和阿立哌唑治疗8周。于治疗前和治疗后2、4、6、8周末采用阳性症状与阴性症状量表（PANSS）评定临床疗效,副反应症状量表（TESS）评定不良反应。结果：治疗8周后两组疗效近似（P〉0.05）,两组有效率差异无显著性（P〉0.05）;阿立哌唑组的副反应发生率高于齐拉西酮组,但差异无显著性（P〉0.05）。两药引起的副反应一般为轻度或中度,患者耐受性较好。结论：齐拉西酮和阿立哌唑治疗精神分裂症均有较好疗效,疗效相当,不良反应较小。

Comparison of efficacy and safety of Aripiprazole and Ziprasidone in the treatment of schizophrenia

Objective:To compare efficacy and safety of Aripiprazo1e and Ziprasidone in the treatment of schizophrenia.Methods:80 patients with schizophrenia by ICD10 were randomly allocated to two groups treated with Aripiprazo1e or Ziprasidone for 8 weeks.The Positive and Negative Syndrom Scale(PANSS) and Treatment Emergent Symptoms Scale(TESS) were used to evaluate efficacy and adverse effects respectively before and at the ends of 2,4,6,8 weeks of treatment.Results:The total effective rates for the Aripiprazole and Ziprasidone groups were similar after 8 weeks(P>0.05).There was no significant difference between the two groups(P>0.05).Incidence of adverse effects in the Aripiprazole group was lower than that in the Ziprasidone group,but the difference was not Significant(P>0.05).Their side effects were not serious,and patients often had good torlerabi1ity for them.Conclusion:The results suggest that Aripiprazo1e is as effective as Ziprasidone for the treatment of schizophrenia,and two agents have low side effects profile.